Clinical and Economic Impact of 2nd Line Initiation of Empagliflozin After Metformin, as Compared to 2nd Line Initiation of Sulfonylurea After Metformin in Patients With Type 2 Diabetes and Cardiovascular Disease
Latest Information Update: 03 Jun 2022
At a glance
- Drugs Empagliflozin (Primary) ; Metformin (Primary) ; Sulfonylureas
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 30 May 2022 Planned initiation date changed from 30 Oct 2021 to 1 Nov 2021.
- 30 May 2022 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 09 May 2022 Planned End Date changed from 30 Apr 2022 to 15 Jun 2022.